Effects of Alogliptin on Pancreatic Beta Cell Function
Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
It is reported that pancreatic beta cell function is already declined at pre-diabetic stage,
impaired glucose tolerance (IGT). It has not been clarified whether inhibitors of the
dipeptidyl peptidase IV enzyme (DPP-IV inhibitors) improve beta cell function on human
pancreas, however, if efficacy is ensured, they may become the first medicine to be chosen
for treatments of type 2 diabetes and IGT.
In this trial, a DPP-IV inhibitor, Alogliptin, or Metformin are given to diabetic patients
whose HbA1c level is below 7.9%. Oral glucose tolerance test (OGTT) will be conducted before,
a year after, and two years after the beginning of the trial and beta cell function will be
evaluated.